The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

regadobiosciences.com

Stage

Acq - P2P

Total Raised

$173.63M

Investors Count

11

Deal Terms

5

Portfolio Exits

1

Regado Biosciences Funding, Regado Biosciences Valuation & Regado Biosciences Revenue

10 Fundings

Regado Biosciences's latest funding round was a IPO for $42M on August 22, 2013.

Regado Biosciences's latest post-money valuation is from August 2013.

Sign up for a free trial to see Regado Biosciences's valuations in August 2013 and more.

Regado Biosciences's 2013 revenue was $8.89M. Regado Biosciences's most recent revenue is from 2013.

Sign up for a free trial to see revenue data from 2013 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

8/22/2013

IPO

$42M

$99M

$0.00B

((9.99x))

FY 1234

1

12/19/2012

Series E

$51M

$8.89M

FY 2013

3

5/21/2012

Convertible Note

$6.78M

$0.00B

((9.99x))

FY 1234

7/1/2011

Series D - II

$99M

0

FY undefined

0

12/17/2009

Series D

$99M

0

FY undefined

10

Date

8/22/2013

12/19/2012

5/21/2012

7/1/2011

12/17/2009

Round

IPO

Series E

Convertible Note

Series D - II

Series D

Amount

$42M

$51M

$6.78M

$99M

$99M

Investors

Valuation

$99M

Revenue

$0.00B

((9.99x))

FY 1234

$8.89M

FY 2013

$0.00B

((9.99x))

FY 1234

0

FY undefined

0

FY undefined

Sources

1

3

0

10

Regado Biosciences Deal Terms

5 Deal Terms

Regado Biosciences's deal structure is available for 5 funding rounds, including their IPO from August 22, 2013.

Round

IPO

Series E

Series C

Series B

Series A

Funding Date

$99M

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

$99M

Post-Money Valuation

$99M

$99M

Amount Raised

$99M

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

Dividend Rate

$99M

$99M

Liquidation Preferences

$99M

$99M

Liquidation Price

Participation

$99M

Conversion Price

Anti Dilution

$99M

$99M

General Voting

$99M

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

IPO

$99M

$99M

$99M

$99M

$99M

$99M

Series E

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Regado Biosciences Investors

11 Investors

Regado Biosciences has 11 investors. Aurora Funds invested in Regado Biosciences's Series E funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

12/24/2004

12/19/2012

7
Series D, Series A (2004), Series B (2005), Series C (2007), Series D - II (2011), Convertible Note (2012), Series E (2012)

B. Jefferson Clark

Venture Capital

North Carolina

8/22/2005

12/19/2012

6
Series D, Series B (2005), Series C (2007), Series D - II (2011), Convertible Note (2012), Series E (2012)

Venture Capital

New Jersey

8/22/2005

12/19/2012

6
Series D, Series B (2005), Series C (2007), Series D - II (2011), Convertible Note (2012), Series E (2012)

Venture Capital

Pennsylvania

00/00/0000

00/00/0000

Andera Partners

Subscribe to see more

Subscribe to see more

Private Equity

France

00/00/0000

00/00/0000

Caxton Advantage Life Sciences Fund

Subscribe to see more

Venture Capital

United States

First funding

12/24/2004

8/22/2005

8/22/2005

00/00/0000

00/00/0000

Last Funding

12/19/2012

12/19/2012

12/19/2012

00/00/0000

00/00/0000

Investor

Andera Partners

Caxton Advantage Life Sciences Fund

Rounds

7
Series D, Series A (2004), Series B (2005), Series C (2007), Series D - II (2011), Convertible Note (2012), Series E (2012)
6
Series D, Series B (2005), Series C (2007), Series D - II (2011), Convertible Note (2012), Series E (2012)
6
Series D, Series B (2005), Series C (2007), Series D - II (2011), Convertible Note (2012), Series E (2012)

Subscribe to see more

Subscribe to see more

Board Seats

B. Jefferson Clark

Subscribe to see more

Type

Venture Capital

Venture Capital

Venture Capital

Private Equity

Venture Capital

Location

North Carolina

New Jersey

Pennsylvania

France

United States

Regado Biosciences Acquisitions

1 Acquisition

Regado Biosciences acquired 1 company. Their latest acquisition was Tobira Therapeutics on May 05, 2015.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/5/2015

Convertible Note

$99M

$75M

Reverse Merger

1

Date

5/5/2015

Investment Stage

Convertible Note

Companies

Valuation

$99M

Total Funding

$75M

Note

Reverse Merger

Sources

1

Regado Biosciences Portfolio Exits

1 Portfolio Exit

Regado Biosciences has 1 portfolio exit. Their latest portfolio exit was Tobira Therapeutics on November 01, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/1/2016

Acq - P2P

$99M

4

Date

11/1/2016

Exit

Acq - P2P

Companies

Valuation

$99M

Acquirer

Sources

4

You May Also Like

A
Altair Therapeutics

Altair Therapeutics is a biotechnology company focused on the discovery, development and commercialization of antisense drugs for respiratory conditions.

C
Chroma Therapeutics

Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.

REGiMMUNE Logo
REGiMMUNE

REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

S
SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

A
Alice Therapeutics

Alice Therapeutics is a biotechnology company.

D
Decimmune Therapeutics

DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's approach is based on the discovery of an innate IgM-mediated auto-immune pathway that is triggered by vascular injury in conditions such as diabetic nephropathy, sickle cell disease, and myocardial infarction. This pathway, dubbed N2, can initiate a cascade of tissue damaging events leading to loss of organ function.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.